Klaus W. Wagner
2021
In 2021, Klaus W. Wagner earned a total compensation of $3.7M as Chief Medical Officer at Inhibrx, a 278% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $180,000 |
|---|---|
| Option Awards | $3,051,966 |
| Salary | $450,000 |
| Other | $14,500 |
| Total | $3,696,466 |
Wagner received $3.1M in option awards, accounting for 83% of the total pay in 2021.
Wagner also received $180K in non-equity incentive plan, $450K in salary and $14.5K in other compensation.
Rankings
In 2021, Klaus W. Wagner's compensation ranked 3,614th out of 12,415 executives tracked by ExecPay. In other words, Wagner earned more than 70.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,614 out of 12,415 | 71st |
Division Manufacturing | 1,472 out of 5,508 | 73rd |
Major group Chemicals And Allied Products | 599 out of 2,378 | 75th |
Industry group Drugs | 533 out of 2,099 | 75th |
Industry Biological Products, Except Diagnostic Substances | 139 out of 449 | 69th |
Source: SEC filing on April 13, 2022.
Wagner's colleagues
We found three more compensation records of executives who worked with Klaus W. Wagner at Inhibrx in 2021.